A practical reference on mass spectrometry: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | Reverse-phase HPLC | Reported as area percentage |
| Identity confirmation | Mass spectrometry | Electrospray or laser desorption |
| Powder storage | Minus 20 degrees Celsius or lower | Dark and dry conditions |
| Solution storage | Two to eight degrees Celsius | Avoid repeated freeze-thaw |
| Appearance | White to off-white powder | Common lyophilized form |
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
== Participation in the creation-evolution debate == Wickramasinghe and his mentor Fred Hoyle have also used their data to argue in favor of cosmic ancestry, and against the idea of life emerging from inanimate objects by abiogenesis.
The sigma σ2 receptor was discovered and named in 1990, and was identified in part due to the dramatically reduced affinity of alazocine for the receptor relative to the σ1 receptor (in contrast to non-selective ligands like haloperidol, ditolylguanidine, and (+)-3-PPP, which show similar affinity for both subtypes). It was encountered as a novel designer drug by 2019.
== Major subtypes == There are four major subtypes of opioid receptors. OGFr was originally discovered and named as a new opioid receptor zeta (ζ). However it was subsequently found that it shares little sequence similarity with the other opioid receptors, and has quite different function.
Diabetes Care. 16 (11): 1470–8. doi:10.2337/diacare.16.11.1470. PMID 8299436. S2CID 23783836. Haakens K., Hanssen K.F.; et al. (1990). "CSII, MDI and conventional insulin therapy in self-selecting insulin-dependent diabetic patients. A comparison of metabolic control acute complications and patient preferences". J Intern Med. 228 (5): 457–464. doi:10.1111/j.1365-2796.1990.tb00263.x. PMID 2254715. S2CID 20197231. Ludvigsson J; et al. (2003). "Continuous Subcutaneous Glucose Monitoring Improved Metabolic Control in Pediatric Patients With Type 1 Diabetes: A Controlled Crossover Study". Pediatrics. 111 (5): 933–8. doi:10.1542/peds.111.5.933. PMID 12728068. S2CID 30709714. Marcus A.O., Fernandez M.P. (1996). "Insulin pump therapy; acceptable alternative to injecting therapy". Postgraduate Medicine. 99: 3. Mudaliar S., Edelman S.V. (2001). "Insulin therapy in type 2 diabetes". Endocrinology and Metabolism Clinics. 39 (4): 935–82. doi:10.1016/s0889-8529(05)70222-x. PMID 11727406. Pitzer KR; et al. (2001). "Detection of Hypoglycemia With the GlucoWatch Biographer". Diabetes Care. 24 (5): 881–885. doi:10.2337/diacare.24.5.881. PMID 11347748. Tsui E.Y.L, Chiasson J.L; et al. (1998). "Counterregulatory hormone responses after long-term CSII with lispro insulin". Diabetes Care. 21 (1): 93–6. doi:10.2337/diacare.21.1.93. PMID 9538976. S2CID 21217439.
Sources: en.wikipedia.org
== Related enzymes == Other enzymes involved in the catabolism of phenylalanine include phenylalanine hydroxylase, aminotransferase, p-hydroxyphenylpyruvate dioxygenase, homogentisate oxidase, and fumarylacetoacetate hydrolase. Mutations in some of these enzymes can lead to more severe diseases such as, phenylketonuria, alkaptonuria, and tyrosinemia. The gene GSTZ1 is located on chromosome 14q24.3.
=== General references === anon, Guidance for Industry:Q8 (R2) Pharmaceutical Development, US FDA, 2009, [1] anon, Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics, May 1999, Food and Drug Administration, Center for Drug Evaluation and Research, [2] Lockhart, H., and Paine, F.A., "Packaging of Pharmaceuticals and Healthcare Products", 2006, Blackie, ISBN 0-7514-0167-6 Pilchik, R., "Validating Medical Packaging" 2002, ISBN 1-56676-807-1 Rosette, J. L, "Improving Tamper-Evident Packaging: Problems, Tests and Solutions", 1992 Soroka, W, "Fundamentals of Packaging Technology", IoPP, 2002, ISBN 1-930268-25-4 Soroka, W, Illustrated Glossary of Packaging Terminology, Institute of Packaging Professionals, [3] Yam, K. L., "Encyclopedia of Packaging Technology", John Wiley & Sons, 2009, ISBN 978-0-470-08704-6
== M == MALDI – Matrix-assisted laser desorption/ionization MBE – Molecular beam epitaxy MEIS – Medium energy ion scattering MFM – Magnetic force microscopy MIT – Magnetic induction tomography MPM – Multiphoton fluorescence microscopy MRFM – Magnetic resonance force microscopy MRI – Magnetic resonance imaging MS – Mass spectrometry MS/MS – Tandem mass spectrometry MSGE – Mechanically stimulated gas emission Mössbauer spectroscopy MTA – Microthermal analysis
Sources: en.wikipedia.org
The Ayrshire and Simmental breeds were imported first, followed by the Brown Swiss, but few people wanted to crossbreed with them because of their large size, and the Japanese government encouraged it, but the crossbreds were very unpopular. The crossbreds' oversized stature made them inconvenient for Japan's narrow arable land, and their movements were slow and sluggish, and their temperaments were rough and lacking in obedience. They also had poor meat quality and were condemned from all quarters as being unsuitable for sukiyaki. As a result, from around 1907, there were no more crossbreds being bred, and in reaction, the old black cattle were considered good, and as long as they were small and black, they could be sold. As crossbreeding with Western breeds progressed, the term "pure Wagyu" (純粋和牛, junsui Wagyū) emerged to describe native Japanese cattle, and by 1912, it was claimed that there were two definitions of Wagyu: "pure Wagyu" and "improved Wagyu" (改良和牛, kairyō Wagyū). At that time, Mendel's laws had just been rediscovered, and both the Japanese government and cattle farmers lacked sufficient knowledge of genetics. The unpopularity of crossbred cattle led to the Japanese government's decision in 1911 to suspend plans to purchase Brown Swiss and Simmental cattle. In 1912, the Japanese government decided to formally end its policy of encouraging crossbreeding by announcing that crossbreeding between Wagyu and European breeds had been sufficiently successful. From then on, Wagyu improvement was based on pure Wagyu and improved Wagyu (crossbred cattle).
=== Nonhematopoietic roles === Erythropoietin was reported to have a range of actions beyond stimulation of erythropoiesis including vasoconstriction-dependent hypertension, stimulating angiogenesis, and promoting cell survival via activation of EPO receptors resulting in anti-apoptotic effects on ischemic tissues. However this proposal is controversial with numerous studies showing no effect. It is also inconsistent with the low levels of EPO receptors on those cells. Clinical trials in humans with ischemic heart, neural and renal tissues have not demonstrated the same benefits seen in animals. In addition some research studies have shown its neuroprotective effect on diabetic neuropathy, however these data were not confirmed in clinical trials that have been conducted on the deep peroneal, superficial peroneal, tibial and sural nerves.
=== Stigma === Heroin users are often referred to as 'amaparas' a term that researchers say is a dehumanizing and derogatory term that implies worthlessness and criminality. The term is perpetuating marginalization and discrimination, while preventing an understanding of the addiction crisis as a medical issue and addicts as people requiring social support.
In mass spectrometry, data-independent acquisition (DIA) is a method of molecular structure determination in which all ions within a selected m/z range are fragmented and analyzed in a second stage of tandem mass spectrometry. Tandem mass spectra are acquired either by fragmenting all ions that enter the mass spectrometer at a given time (called broadband DIA) or by sequentially isolating and fragmenting ranges of m/z. DIA is an alternative to data-dependent acquisition (DDA) where a fixed number of precursor ions are selected and analyzed by tandem mass spectrometry.
Sources: en.wikipedia.org
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.
Reverse-phase high-performance liquid chromatography is used for purity. Mass spectrometry confirms molecular weight and sequence integrity. Amino acid analysis offers an additional compositional check.
Published stability data for dissolved material are limited and vary with conditions. Refrigerated solutions are generally used within a short period. The exact shelf life depends on concentration, buffer, and handling.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.